Pleural diffuse mesothelial lesions: A challenge for pathologists

Malignant mesothelioma (MM) is a highly aggressive tumor deriving from the mesothelial cells normally lining the body cavities.  Histologically, MM is classified in three major histopathological patterns, such as epithelioid, sarcomatoid and mixed type. It is well known that the diagnosis of MM can be very challenging, especially in small bioptic fragments or cytological specimens. The most common diagnostic pitfalls involve the distinction between primary epithelioid MM and metastatic adenocarcinoma as well as that between reactive epithelial/fibrous benign proliferations and MM. Recently, a pathologist’s panel suggested new practical strategies and recommendations for the MM diagnosis, regarding the interpretation of histo-cytological features and the composition of appropriate immunohistochemical algorithm. Finally, according to the updated international guidelines, morphological data require a careful clinico-pathological correlation to achieve an accurate diagnosis of pleural lesions.

[1]  F. Galateau-Sallé,et al.  The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. , 2017, Human pathology.

[2]  J. Vergnon,et al.  Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies , 2017, Virchows Archiv.

[3]  A. Husain,et al.  BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. , 2017, Human pathology.

[4]  T. Tsuchida,et al.  Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis , 2016, PloS one.

[5]  G. Scagliotti,et al.  BRCA1‐Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  K. Nabeshima,et al.  Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations , 2016, Diagnostic cytopathology.

[7]  A. Gown,et al.  BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas , 2016, The American journal of surgical pathology.

[8]  F. Galateau-Sallé,et al.  The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  A. Husain,et al.  Malignant Mesothelioma Diagnosis. , 2015, Archives of pathology & laboratory medicine.

[10]  C. Bedrossian An update on pleuro‐pulmonary cytopathology: Part i: Cytological diagnosis of mesothelioma and molecular cytology of lung cancer with an historical perspective , 2015, Diagnostic cytopathology.

[11]  A. Fassina,et al.  Guidelines for the cytopathologic diagnosis of epithelioid and mixed‐type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology , 2015, Diagnostic cytopathology.

[12]  V. Ascoli Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines. , 2015, Annali dell'Istituto superiore di sanita.

[13]  A. Fassina,et al.  Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma , 2015, Acta Cytologica.

[14]  D. Henderson,et al.  Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA , 2013, Journal of Clinical Pathology.

[15]  D. Henderson,et al.  Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers , 2013, Journal of Clinical Pathology.

[16]  V Torri,et al.  Malignant Pleural Mesothelioma : State of the art and recommendations , 2016 .

[17]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. , 2013, Archives of pathology & laboratory medicine.

[18]  P. Betta,et al.  Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma. , 2012, Archives of pathology & laboratory medicine.

[19]  D. Henderson,et al.  Molecular biomarkers in malignant mesothelioma: state of the art , 2011, Pathology.

[20]  F. Demirağ,et al.  Benign and Malignant Mesothelial Proliferation. , 2010, Surgical pathology clinics.

[21]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. , 2009, Archives of pathology & laboratory medicine.

[22]  B. Addis,et al.  Problems in mesothelioma diagnosis , 2009, Histopathology.

[23]  S. Suster,et al.  Applications and Limitations of Immunohistochemistry in the Diagnosis of Malignant Mesothelioma , 2006, Advances in anatomic pathology.

[24]  J. Silverman,et al.  The Diagnosis of Malignancy in Effusion Cytology: A Pattern Recognition Approach , 2006, Advances in anatomic pathology.

[25]  Immunohistochemical Diagnostic Approach in Neoplastic Pathology of Mesothelium , 2018 .

[26]  G. Alí,et al.  The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. , 2018, Journal of thoracic disease.

[27]  G. Alí,et al.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. , 2018, Journal of thoracic disease.

[28]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.

[29]  S. Monaco,et al.  Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples , 2018, Advances in anatomic pathology.

[30]  A. Gown,et al.  Guidelines for Pathologic Diagnosis of Malignant Mesothelioma , 2017 .

[31]  N. Maskell,et al.  Biopsy techniques for the diagnosis of mesothelioma. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[32]  Markus Voelter,et al.  State of the Art , 1997, Pediatric Research.